The effect of an adenosine A 2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

ConclusionsAlthough previously shown to be efficacious in rodents to increase varied size agents to cross the BBB, our data suggest that regadenoson does not increase temozolomide concentrations in brain. Further studies exploring alternative doses and schedules are needed; as transiently disrupting the BBB to facilitate drug entry is of critical importance in neuro-oncology.
Source: Fluids and Barriers of the CNS - Category: Neuroscience Source Type: research